Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study

Sharon D Solomon1 Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USACorrespondence[email protected]

Victoria Kyerematen2 Bloomfield Court Hospital, National Health Services, London, UK

Madiha Qutab3 Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Adam S Wenick1 Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Jiangxia Wang4 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA

Barbara S Hawkins1 Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA;4 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA

References

Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
PubMed Web of Science ®Google Scholar
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
PubMed Web of Science ®Google Scholar
Maguire MG, Martin DF, Ying G-S; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Five-Year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751–1761. doi:10.1016/j.ophtha.2016.03.045
PubMed Web of Science ®Google Scholar
Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;8:CD005139.
PubMed Web of Science ®Google Scholar
Prenner JL, Halperin LS, Rycroft C, et al. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160(4):725–731. doi:10.1016/j.ajo.2015.06.023
PubMed Web of Science ®Google Scholar
Patel Y, Miller DM, Fung AE, Hill LF, Rosenfeld PJ. Are dilated fundus examinations needed for OCT-guided retreatment of exudative age-related macular degeneration? Ophthalmol Retina. 2020;4(2):141–147. doi:10.1016/j.oret.2019.09.006
Google Scholar
Rand Corporation: Visit-Specific Satisfaction Instrument (VSQ-9). Available from: https://www.rand.org/health-care/surveys_tools/vsq9.html. Accessed August 06, 2017.
Google Scholar

Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date